Unknown

Dataset Information

0

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.


ABSTRACT: Treatment with Daratumumab (Dara), a monoclonal anti-CD38 antibody of IgG1 subtype, is effective in patients with multiple myeloma (MM). However, Dara also impairs the cellular immunity, which in turn may lead to higher susceptibility to infections. The exact link between immune impairment and infectious complications is unclear. In this study, we report that nine out of 23 patients (39%) with progressive MM had infectious complications after Dara treatment. Five of these patients had viral infections, two developed with bacterial infections and two with both bacterial and viral infections. Two of the viral infections were exogenous, i.e. acute respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), while five consisted of reactivations, i.e. one herpes simplex (HSV), 1 varicella-zoster (VZV) and three cytomegalovirus (CMV). Infections were solely seen in patients with partial response or worse. Assessment of circulating lymphocytes indicated a selective depletion of NK cells and viral reactivation after Dara treatment, however this finding does not exclude the multiple components of viral immune-surveillance that may get disabled during this monoclonal treatment in this patient cohort. These results suggest that the use of antiviral and antibacterial prophylaxis and screening of the patients should be considered.

SUBMITTER: Nahi H 

PROVIDER: S-EPMC6374018 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.

Nahi Hareth H   Chrobok Michael M   Gran Charlotte C   Lund Johan J   Gruber Astrid A   Gahrton Gösta G   Ljungman Per P   Wagner Arnika Kathleen AK   Alici Evren E  

PloS one 20190213 2


Treatment with Daratumumab (Dara), a monoclonal anti-CD38 antibody of IgG1 subtype, is effective in patients with multiple myeloma (MM). However, Dara also impairs the cellular immunity, which in turn may lead to higher susceptibility to infections. The exact link between immune impairment and infectious complications is unclear. In this study, we report that nine out of 23 patients (39%) with progressive MM had infectious complications after Dara treatment. Five of these patients had viral infe  ...[more]

Similar Datasets

| S-EPMC4069139 | biostudies-other
| S-EPMC10155898 | biostudies-literature
| S-EPMC8234557 | biostudies-literature
| S-EPMC6095810 | biostudies-literature
| S-EPMC9907188 | biostudies-literature
| S-EPMC8392190 | biostudies-literature
| S-EPMC9006279 | biostudies-literature
| S-EPMC10656693 | biostudies-literature
| S-EPMC7685974 | biostudies-literature
| S-EPMC5395289 | biostudies-literature